Scholarlink

Background <p>Post-translational modification is crucial, with acetylation and deacetylation enzymes playing important roles. Their roles in liver cancer, however, remain unclear.</p> Methods <p>In this study, a KAT + KDAC score was developed to assess the prognosis and response to immunotherapy in liver cancer patients. The association of HDAC1, HDAC2, and HDAC3 with patient prognosis was analyzed, and the PPI network was constructed. The correlation between the score and P53 mutation status, stage, and TNM staging was also investigated. Additionally, the response to chemotherapy was evaluated. The TIDE score was also assessed.</p> Results <p>Our analysis showed that HDAC1, HDAC2, and HDAC3 are highly associated with patient prognosis and are centrally located in the PPI network. Patients with high KAT + KDAC scores had a better prognosis, and the score correlated with P53 mutation status, stage, and TNM staging. Notably, patients with low KAT + KDAC scores demonstrate resistance to cisplatin and gemcitabine, and have a lower TIDE score. Moreover, the KAT + KDAC score accurately predicted patient response to immunotherapy.</p> Conclusion <p>The KAT + KDAC modification pattern is critical in the initiation and progression of liver cancer. This score can be used to predict patient prognosis and immunotherapy response. Future studies are needed to further explore the underlying mechanisms and potential therapeutic applications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic and immunotherapeutic response prediction in hepatocellular carcinoma: role of non-histone acetylation/deacetylation scoring

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月7日

查看全文
  • Jizhen Li,
  • Sisi Huang,
  • Fangling Yuan,
  • Xunjun Yang,
  • Qipeng Xie

摘要

Background

Post-translational modification is crucial, with acetylation and deacetylation enzymes playing important roles. Their roles in liver cancer, however, remain unclear.

Methods

In this study, a KAT + KDAC score was developed to assess the prognosis and response to immunotherapy in liver cancer patients. The association of HDAC1, HDAC2, and HDAC3 with patient prognosis was analyzed, and the PPI network was constructed. The correlation between the score and P53 mutation status, stage, and TNM staging was also investigated. Additionally, the response to chemotherapy was evaluated. The TIDE score was also assessed.

Results

Our analysis showed that HDAC1, HDAC2, and HDAC3 are highly associated with patient prognosis and are centrally located in the PPI network. Patients with high KAT + KDAC scores had a better prognosis, and the score correlated with P53 mutation status, stage, and TNM staging. Notably, patients with low KAT + KDAC scores demonstrate resistance to cisplatin and gemcitabine, and have a lower TIDE score. Moreover, the KAT + KDAC score accurately predicted patient response to immunotherapy.

Conclusion

The KAT + KDAC modification pattern is critical in the initiation and progression of liver cancer. This score can be used to predict patient prognosis and immunotherapy response. Future studies are needed to further explore the underlying mechanisms and potential therapeutic applications.